Home > Compound List > Product Information
Desoxycorticosterone Pivalate_Molecular_structure_CAS_808-48-0)
Click picture or here to close

Desoxycorticosterone Pivalate

Catalog No. DB01134 Name DrugBank
CAS Number 808-48-0 Website http://www.ualberta.ca/
M. F. C26H38O4 Telephone (780) 492-3111
M. W. 414.57752 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 1005

SYNONYMS

IUPAC name
2-{2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl}-2-oxoethyl 2,2-dimethylpropanoate
IUPAC Traditional name
desoxycorticosterone pivalate
Brand Name
Cortexone M
Neodin-Depositum
Percorten
Percorten M
Percorten Pivalate
Synonyms
DTMA
Deoxycorticosterone Pivalate
Desoxycortone Pivalate
DOCP
Desoxycorticosterone Trimethylacetate
Deoxycortone Trimethylacetate
Deoxycortone Pivalate
Deoxycortolone Pivalate
Deoxycorticosterone Trimethylacetate

DATABASE IDS

CAS Number 808-48-0
PubChem SID 46506381
PubChem CID 13126

PROPERTIES

Hydrophobicity(logP) 4
Solubility Insoluble

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Desoxycorticosterone Pivalate is a mineralocorticoid hormone and an analog of desoxycorticosterone. It is white, odorless, and stable in air. It is practically insoluble in water, sparingly soluble in acetone, slightly soluble in methanol, ether and vegetable oils. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
Indication Examined for treatment of adrenocortical insufficiency especially in multiple sclerosis, congenital cerebral palsy, polyarteritis nodosa, and rheumatoid arthritis. Currently only approved in treating cats and dogs for the treatment of Addison's disease.
Pharmacology Used to treat adrenocortical insufficiency, desoxycorticosterone pivalate is a mineralocorticoid hormone and an analogue of desoxycorticosterone. It primarily acts on the metabolism of sodium, potassium and water. When the drug is given, there is decreased excretion of sodium accompanied by increased excretion of potassium; the concentration of sodium in the blood is thereby increased whereas that of potassium is decreased. There is a concomitant increase in the volume of blood and extracellular fluids, with a fall in hematocrit. It increases the rate of renal tubular absorption of sodium.
Toxicity Symptoms of overdose include polyuria, polydipsia, increased blood volume, edema, and cardiac enlargement.
Affected Organisms
Humans and other mammals
Protein Binding 90%

REFERENCES